Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine
✍ Scribed by Hana Závadová; Ervin Adam; Vladimír Vonka; Eva Domorázková; Marie KratochvÍlová; Václav Burian; Fred. M. Davenport
- Publisher
- Springer Vienna
- Year
- 1972
- Tongue
- English
- Weight
- 501 KB
- Volume
- 36
- Category
- Article
- ISSN
- 1432-8798
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The influenza virus, major surface glycoprotein hemagglutinin (HA) is one of the principal targets for the development of protective immunity. Aiming at contributing to the development of a vaccine that remains the first choice for prophylactic intervention, a reconstituted model of HA,
Background: Protection against vaccine-preventable diseases is important in inflammatory bowel disease (IBD) because of increased susceptibility and severity of infection with immunosuppressive therapy. However, immunosuppressive therapy may affect vaccine response. This study aimed to evaluate immu
## Abstract Purified subunit vaccines (HANAflu) containing 20 /xg of hemagglutinin of influenza A/USSR/90/77 (H1N1) alone or with 1–5% whole virus were compared to commercially available vaccines for reactogenicity and immunogenicity in unprimed young adults. Reactions to all vaccines were minimal.